Decision to list medical devices supplied by Johnson and Johnson (New Zealand) Limited

Hospital devices Decision

We are pleased to announce the approval of a listing agreement for the supply of medical devices to DHBs.

What we’re doing

We are pleased to announce the approval of the non-exclusive listing agreement with Johnson & Johnson (New Zealand) Limited (“J&J”) for the supply of:

This will result in 337 of J&J’s medical devices, across these categories, being listed in Part III of Section H of the Pharmaceutical Schedule from 1 April 2021.

DHBs will be able to continue to purchase other suppliers’ brands of endomechanical and electrosurgical products and SSCWD products as the agreement is not for sole supply.

Any changes to the original proposal?

This decision was subject to a consultation letter dated 10 February 2021.

There were no changes made to the Agreement as a result of the consultation feedback.

Who we think will be most interested

  • DHB Staff
    • Clinical engineers
    • Surgeons
    • Perioperative staff
    • Theatre staff
    • Central sterile services personnel
    • Surgical and general ward staff
    • Procurement and supply chain personnel
  • Suppliers and wholesalers

Details about this decision

In 2018 PHARMAC issued a Request for Proposals (“RFPs”) for:

The RFPs requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule.

Following evaluation of J&Js responses to each RFP, and consultation on the provisional agreement reached, PHARMAC has decided to list J&J’s ranges of endomechanical and electrosurgical products and SSCWD Products in Part III of Section H of the Pharmaceutical Schedule from 1 April 2021.

The brands and number of products per category included in the J&J Agreement are:



Line items

SSCWD products

  • Blake
  • J-Vac


Endomechanical and electrosurgical products

  • Echelon ranges
  • EES
  • Endopath ranges
  • Endopouch
  • Enseal
  • Ethicon
  • ETS
  • Harmonic ranges
  • Laprya-TY
  • Ligaclip
  • Ligamax
  • Megadyne ranges
  • Proximate PPH



The list of products will be available on PHARMAC’s website from 1 April 2021, in both PDF and Excel spreadsheet formats.

DHBs that purchase these categories of medical devices from J&J must do so under the terms and conditions, and at the prices included in the agreement from the listing date. DHBs can continue to choose which Endomechanical and Electrosurgical Products, and SSCWD products they purchase.

The agreement includes terms and conditions for training and education to be provided by J&J, on the appropriate use of their products, which is to be provided at times as agreed with individual DHBs.

Our response to what you told us

We appreciate the time people took to respond to this consultation.

All consultation responses received by 12 noon on Wednesday 3 March 2021 were considered in their entirety in making the decision to approve this agreement.

A summary of the main themes raised in feedback and our responses to the feedback are set out below:



No technical or resource impacts are expected as a result of the proposal


Noted that DHB volume and expenditure data needed updating to reflect most recent activity for further clarification for validation purposes.

Updated DHB volume and expenditure data was requested from J&J and provided to appropriate DHB personnel prior to closure of the consultation.

Support the non-exclusivity of the agreement, also noting need for training and education on use of products would be required.


If you have any questions about this decision, you can email us at; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.